SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jul 6, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago
Insider cluster: 2 insiders, $478K total
Actionable Insight • Neutral

The cluster is too small to signal a change in fundamentals. Monitor for any >$8M insider sales (0.1% of market cap) that would be material. The prior 30-day insider activity of $1.1M in total sales also remains below the threshold.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$60.67
T+0 close · Jul 6, 2026 · via day close
Latest settled
−6.21%
T+60 · $56.90
Vs SPY
−8.21%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 7 $60.67entry
  2. T+1 · 4mo ago −3.23%α −2.92% · $58.71
  3. T+5 · 4mo ago −7.35%α −7.90% · $56.21
  4. T+20 · 4mo ago −11.77%α −13.10% · $53.53
  5. T+60 · 7w ago −6.21%α −8.21% · $56.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two C-suite insiders at Vaxcyte (PCVX) sold shares worth $478K in the past week, but the amount is negligible relative to the $8.4B market cap (0.006%). The trades are routine option exercises and small share sales, not indicative of a bearish view.

Key Financial Metrics

Direction
selling
Total Value
$478.0K
Insiders
2

Key Facts

  • President and CFO Andrew Guggenhime sold 7,900 shares for $452K on July 6, 2026.
  • COO Jim Wassil sold 456 shares for $26K on July 1, 2026.
  • Total open-market sales of $478K represent ~0.006% of market cap, well below the 0.1% materiality threshold.
  • Both transactions followed derivative exercises (non-cash events), typical for tax withholding and profit-taking.

Financial Impact

Insider sales of $478K are trivial relative to $8.4B market cap.

insider_ownershipdilution

Risk Factors

  • Insider selling could accelerate if the stock continues to rise, but the current magnitude is routine.
  • No other recent filings (e.g., earnings, restatements) to contextualize the sales, treat as standalone liquidity events.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-PCVX-1783382471838

US Market Status

Market Closed · Opens Wed (13h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 6, 2026